KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $4.2 million.

  • Ionis Pharmaceuticals' Interest Expenses rose 122.57% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.6 million, marking a year-over-year decrease of 423.39%. This contributed to the annual value of $17.0 million for FY2024, which is 3423.38% up from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Interest Expenses of $4.2 million as of Q3 2025, which was up 122.57% from $4.1 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Interest Expenses ranged from a high of $4.6 million in Q4 2023 and a low of $1.6 million during Q1 2023
  • Over the past 5 years, Ionis Pharmaceuticals' median Interest Expenses value was $2.4 million (recorded in 2021), while the average stood at $3.1 million.
  • Examining YoY changes over the last 5 years, Ionis Pharmaceuticals' Interest Expenses showed a top increase of 16331.6% in 2023 and a maximum decrease of 2422.24% in 2023.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Interest Expenses stood at $2.2 million in 2021, then decreased by 22.65% to $1.7 million in 2022, then surged by 163.32% to $4.6 million in 2023, then dropped by 8.05% to $4.2 million in 2024, then rose by 0.5% to $4.2 million in 2025.
  • Its Interest Expenses stands at $4.2 million for Q3 2025, versus $4.1 million for Q2 2025 and $4.1 million for Q1 2025.